News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AmpliMed Corporation to Present Clinical Data from Three Clinical Trials of Amplimexon® at American Society of Clinical Oncology Annual Meeting



5/30/2008 10:19:43 AM

TUCSON, Ariz.--(BUSINESS WIRE)--AmpliMed Corporation, a cancer therapeutics company, today announced that data from three clinical trials of Amplimexon® in various cancer types will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 to June 3, 2008, at McCormick Place in Chicago. Investigators will present final results from a Phase 1/2 trial of Amplimexon (imexon for injection) in metastatic melanoma, updated data from a Phase 1 trial of Amplimexon in combination with docetaxel (Taxotere) in breast, lung and prostate cancer and updated data from a Phase 1 trial of Amplimexon in combination with gemcitabine (Gemzar®) in advanced pancreatic cancer.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES